Baird Downgrades Ra Pharma (RARX) to Neutral Following Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts RARX Hot Sheet
Price: $48.00 --0%
Rating Summary:
0 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
0 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Baird analyst Madhu Kumar downgraded Ra Pharma (NASDAQ: RARX) from Outperform to Neutral with a price target of $48.00 (from $38.00).
For an analyst ratings summary and ratings history on Ra Pharma click here. For more ratings news on Ra Pharma click here.
Shares of Ra Pharma closed at $22.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Seaport Global Securities Downgrades Intel (INTC) to Neutral
- Freedom Broker Downgrades Luxfer Holdings PLC (LXFR) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
